Vertex CEO takes Morgan Stanley analyst to task at conference

Vertex Pharmaceuticals ($VRTX) CEO Matthew Emmens didn't stick with the script at yesterday's Morgan Stanley Global Healthcare Conference. Armed with stellar early sales figures for Vertex's new hep C drug Incivek, Emmens scolded the investment bank's own analyst David Friedman, accusing him of failing to understand the company. Report

Suggested Articles

The Trump administration has selected five COVID-19 vaccines for Operation Warp Speed, the NYT reports, with Big Pharma dominating the list.

Racing with some COVID-19 vaccine heavyweights, Novavax has brought on a partner to manufacture adjuvant for its in-development shot. 

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.